INBX
Inhibrx Biosciences, Inc.
Price Chart
Latest Quote
$93.88
-1.15 (-1.21%)
Current Price
| Previous Close | $95.03 |
| Open | $95.57 |
| Day High | $98.50 |
| Day Low | $93.16 |
| Volume | 61,509 |
Stock Information
| Shares Outstanding | 14.67M |
| Total Debt | $180.90M |
| Cash Equivalents | $161.66M |
| Revenue | $1.30M |
| Net Income | $-130.19M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.38B |
| EPS (TTM) | $-8.39 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.42B |
| Sales | $1.30M |
| Income | $-130.19M |
| Book/sh | $-1.44 |
| Cash/sh | $11.02 |
| Employees | 109 |
Financial Ratios
| Quick Ratio | 6.11 |
| Current Ratio | 6.46 |
Returns & Margins
| ROA | -36.06% |
| ROE | -354.69% |
| Operating Margin | -9465.46% |
Ownership
| Insider Ownership | 23.16% |
| Institutional Ownership | 83.07% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -14.90 |
| P/S | 1059.49 |
| P/B | -65.19 |
Analyst Data
| Recommendation | none |
| Target Price | $277.50 |
Technical Indicators
| SMA20 | $93.85 |
| SMA50 | $105.80 |
| SMA200 | $76.37 |
| RSI | 56.49 |
| ATR | 6.3838 |
| Shares Float | 8.37M |
| Short Float | 28.96% |
| Short Ratio | 6.19 |
| Volatility | 3.32 |
| Rel Volume | 0.20 |
Performance History
| Week | -0.34% |
| Month | -12.14% |
| Quarter | +41.26% |
| 6 Months | +7.27% |
| YTD | +25.11% |
| Year | +536.04% |
| 10 Years | +650.64% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $93.88 | 61,508 |
| 2026-06-24 | $95.14 | 316,200 |
| 2026-06-23 | $92.91 | 342,800 |
| 2026-06-22 | $93.30 | 235,300 |
| 2026-06-18 | $93.05 | 473,500 |
| 2026-06-17 | $94.20 | 269,200 |
| 2026-06-16 | $93.11 | 331,200 |
| 2026-06-15 | $93.51 | 380,100 |
| 2026-06-12 | $92.20 | 263,300 |
| 2026-06-11 | $93.54 | 359,500 |
| 2026-06-10 | $89.47 | 399,000 |
| 2026-06-09 | $89.10 | 248,100 |
| 2026-06-08 | $89.13 | 194,500 |
| 2026-06-05 | $87.01 | 417,400 |
| 2026-06-04 | $91.25 | 388,700 |
| 2026-06-03 | $95.22 | 328,000 |
| 2026-06-02 | $93.63 | 320,600 |
| 2026-06-01 | $99.29 | 261,400 |
| 2026-05-29 | $104.01 | 245,100 |
| 2026-05-28 | $103.98 | 369,200 |
| 2026-05-27 | $103.00 | 243,700 |
| 2026-05-26 | $106.85 | 228,800 |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
đ° Latest News
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Insider Monkey âĸ 2026-05-14T16:52:03Z
Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors?
Simply Wall St. âĸ 2026-05-12T14:12:39Z
Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds
Simply Wall St. âĸ 2026-05-12T10:07:11Z
Inhibrx Biosciencesâ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
MarketBeat âĸ 2026-05-11T16:08:17Z
This Biotech Stock Surges After Positive Cancer Trial Results. What to Know.
Barrons.com âĸ 2026-05-11T15:51:00Z
Inhibrx delivers âdifferentiatedâ cancer drug data; Fractyl starts diabetes gene therapy trial
BioPharma Dive âĸ 2026-05-11T10:00:00Z
Assessing Inhibrx Biosciences (INBX) Valuation After Ozekibart Data And Regulatory Momentum
Simply Wall St. âĸ 2026-05-02T02:17:22Z
Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans
Simply Wall St. âĸ 2026-04-26T23:05:44Z
Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer
MarketBeat âĸ 2026-04-25T11:12:35Z
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Zacks âĸ 2026-04-23T13:33:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $1,300,000 | $200,000 | $1,800,000 | $1,301,000 |
| Operating Revenue | $1,300,000 | $200,000 | $1,800,000 | $1,301,000 |
| Expenses | ||||
| Interest Expense | $12,196,000 | $13,491,000 | $31,840,000 | - |
| Total Expenses | $136,325,000 | $331,648,000 | $221,021,000 | $116,624,000 |
| Other Income Expense | $-381,000 | $2,021,573,000 | $-580,000 | $1,000 |
| Other Non Operating Income Expenses | $-381,000 | $75,000 | $-580,000 | $1,000 |
| Net Non Operating Interest Income Expense | $-4,647,000 | $-2,551,000 | $-19,923,000 | - |
| Interest Expense Non Operating | $12,196,000 | $13,491,000 | $31,840,000 | - |
| Operating Expense | $136,325,000 | $331,648,000 | $221,021,000 | $116,624,000 |
| General And Administrative Expense | $23,118,000 | $127,501,000 | $29,381,000 | $15,035,000 |
| Other Operating Expenses | - | - | - | $-14,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-140,055,000 | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Net Interest Income | $-4,647,000 | $-2,551,000 | $-19,923,000 | - |
| Interest Income | $7,549,000 | $10,940,000 | $11,917,000 | - |
| Normalized Income | $-140,055,000 | $-333,923,604 | $-241,361,000 | $-115,325,000 |
| Net Income From Continuing And Discontinued Operation | $-140,055,000 | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Total Operating Income As Reported | $-135,025,000 | $-331,448,000 | $-219,221,000 | $-115,323,000 |
| Net Income Common Stockholders | $-140,055,000 | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Net Income | $-140,055,000 | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Net Income Including Noncontrolling Interests | $-140,055,000 | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Net Income Continuous Operations | $-140,055,000 | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Pretax Income | $-140,053,000 | $1,687,574,000 | $-239,724,000 | $-115,322,000 |
| Special Income Charges | $0 | $2,021,498,000 | $0 | - |
| Interest Income Non Operating | $7,549,000 | $10,940,000 | $11,917,000 | - |
| Operating Income | $-135,025,000 | $-331,448,000 | $-219,221,000 | $-115,323,000 |
| Depreciation Amortization Depletion Income Statement | $179,000 | $404,000 | - | - |
| Depreciation And Amortization In Income Statement | $179,000 | $404,000 | - | - |
| Earnings From Equity Interest Net Of Tax | - | $0 | $-1,634,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-9.04 | $112.62 | $-16.95 | $-8.10 |
| Basic EPS | $-9.04 | $114.01 | $-16.95 | $-8.10 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $2,396 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-125,374,000 | $-318,148,000 | $-206,693,000 | $-114,098,000 |
| Total Unusual Items | $0 | $2,021,498,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $2,021,498,000 | $0 | - |
| Reconciled Depreciation | $2,483,000 | $2,285,000 | $1,191,000 | $1,225,000 |
| EBITDA (Bullshit earnings) | $-125,374,000 | $1,703,350,000 | $-206,693,000 | $-114,098,000 |
| EBIT | $-127,857,000 | $1,701,065,000 | $-207,884,000 | $-115,323,000 |
| Diluted Average Shares | $15,487,000 | $14,984,000 | $14,241,175 | $14,241,175 |
| Basic Average Shares | $15,487,000 | $14,802,000 | $14,241,175 | $14,241,175 |
| Diluted NI Availto Com Stockholders | $-140,055,000 | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Tax Provision | $2,000 | $2,000 | $3,000 | $3,000 |
| Restructuring And Mergern Acquisition | $0 | $-2,021,498,000 | $0 | - |
| Research And Development | $113,028,000 | $203,743,000 | $191,640,000 | $101,603,000 |
| Selling General And Administration | $23,118,000 | $127,501,000 | $29,381,000 | $15,035,000 |
| Other Gand A | $23,118,000 | $127,501,000 | $29,381,000 | $15,035,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $7,993,000 | $133,584,000 | $43,503,000 | $-7,300,000 |
| Total Assets | $146,478,000 | $180,767,000 | $307,893,000 | $16,645,000 |
| Total Non Current Assets | $13,646,000 | $20,369,000 | $12,535,000 | $10,382,000 |
| Other Non Current Assets | $4,378,000 | $6,831,000 | $3,164,000 | $3,164,000 |
| Current Assets | $132,832,000 | $160,398,000 | $295,358,000 | $6,263,000 |
| Other Current Assets | $1,541,000 | $1,198,000 | $1,094,000 | $674,000 |
| Prepaid Assets | $6,894,000 | $6,184,000 | $15,562,000 | $5,332,000 |
| Receivables | $177,000 | $420,000 | $778,000 | $257,000 |
| Other Receivables | $177,000 | $197,000 | - | - |
| Accounts Receivable | $0 | $200,000 | $778,000 | $243,000 |
| Cash Cash Equivalents And Short Term Investments | $124,220,000 | $152,596,000 | $277,924,000 | - |
| Cash And Cash Equivalents | $124,220,000 | $152,596,000 | $277,924,000 | - |
| Debt | ||||
| Total Debt | $107,012,000 | $8,048,000 | $210,141,000 | $5,033,000 |
| Long Term Debt And Capital Lease Obligation | $104,686,000 | $6,453,000 | $208,078,000 | $3,173,000 |
| Long Term Debt | $100,559,000 | - | $206,968,000 | - |
| Current Debt And Capital Lease Obligation | $2,326,000 | $1,595,000 | $2,063,000 | $1,860,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $138,485,000 | $47,183,000 | $264,390,000 | $23,945,000 |
| Total Non Current Liabilities Net Minority Interest | $104,686,000 | $6,453,000 | $208,078,000 | $3,173,000 |
| Current Liabilities | $33,799,000 | $40,730,000 | $56,312,000 | $20,772,000 |
| Payables And Accrued Expenses | $24,023,000 | $31,409,000 | $47,743,000 | $15,538,000 |
| Interest Payable | $857,000 | $0 | $2,348,000 | - |
| Payables | $5,944,000 | $9,245,000 | $10,954,000 | $4,343,000 |
| Accounts Payable | $5,944,000 | $9,245,000 | $10,954,000 | $4,343,000 |
| Equity | ||||
| Common Stock Equity | $7,993,000 | $133,584,000 | $43,503,000 | $-7,300,000 |
| Total Equity Gross Minority Interest | $7,993,000 | $133,584,000 | $43,503,000 | $-7,300,000 |
| Stockholders Equity | $7,993,000 | $133,584,000 | $43,503,000 | $-7,300,000 |
| Retained Earnings | $-246,187,000 | $-106,132,000 | $-613,734,000 | - |
| Other Equity Interest | - | - | $-7,973,000 | $-7,300,000 |
| Other | ||||
| Ordinary Shares Number | $14,577,609 | $14,475,904 | $14,241,175 | $14,241,175 |
| Share Issued | $14,577,609 | $14,475,904 | $14,241,175 | $14,241,175 |
| Tangible Book Value | $7,993,000 | $133,584,000 | $43,503,000 | $-7,300,000 |
| Invested Capital | $108,552,000 | $133,584,000 | $250,471,000 | $-7,300,000 |
| Working Capital | $99,033,000 | $119,668,000 | $239,046,000 | $-14,509,000 |
| Capital Lease Obligations | $6,453,000 | $8,048,000 | $3,173,000 | $5,033,000 |
| Total Capitalization | $108,552,000 | $133,584,000 | $250,471,000 | $-7,300,000 |
| Additional Paid In Capital | $254,179,000 | $239,715,000 | $657,232,000 | - |
| Capital Stock | $1,000 | $1,000 | $5,000 | - |
| Common Stock | $1,000 | $1,000 | $5,000 | - |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $4,127,000 | $6,453,000 | $1,110,000 | $3,173,000 |
| Current Capital Lease Obligation | $2,326,000 | $1,595,000 | $2,063,000 | $1,860,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,450,000 | $7,726,000 | $6,506,000 | $3,374,000 |
| Current Accrued Expenses | $18,079,000 | $22,164,000 | $36,789,000 | $11,195,000 |
| Net PPE | $9,268,000 | $13,538,000 | $9,371,000 | $7,218,000 |
| Accumulated Depreciation | $-11,121,000 | $-8,893,000 | $-6,687,000 | $-5,540,000 |
| Gross PPE | $20,389,000 | $22,431,000 | $16,058,000 | $12,758,000 |
| Leases | $795,000 | $795,000 | $441,000 | $441,000 |
| Other Properties | $5,535,000 | $7,338,000 | $2,952,000 | $4,717,000 |
| Machinery Furniture Equipment | $14,059,000 | $14,298,000 | $9,073,000 | $7,600,000 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $0 | $23,000 | $0 | $14,000 |
| Construction In Progress | - | $0 | $3,592,000 | $0 |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-129,825,000 | $-197,006,000 | $-197,902,000 | $-91,497,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-129,794,000 | $-194,409,000 | $-193,309,000 | $-90,811,000 |
| Cash Flow From Continuing Operating Activities | $-129,794,000 | $-194,409,000 | $-193,309,000 | $-90,811,000 |
| Operating Gains Losses | $12,000 | $-1,998,797,000 | $1,637,000 | $19,000 |
| Investing Activities | ||||
| Capital Expenditure | $-31,000 | $-2,597,000 | $-4,593,000 | $-686,000 |
| Investing Cash Flow | $-28,000 | $-2,597,000 | $-4,593,000 | $-686,000 |
| Cash Flow From Continuing Investing Activities | $-28,000 | $-2,597,000 | $-4,593,000 | $-686,000 |
| Financing Activities | ||||
| Financing Cash Flow | $101,446,000 | $71,678,000 | $201,961,000 | $91,497,000 |
| Cash Flow From Continuing Financing Activities | $101,446,000 | $71,678,000 | $201,961,000 | $91,497,000 |
| Net Other Financing Charges | $-125,000 | - | $-355,000 | $91,497,000 |
| Issuance Of Capital Stock | - | $0 | $200,000,000 | - |
| Net Common Stock Issuance | - | $0 | $200,000,000 | - |
| Common Stock Issuance | - | $0 | $200,000,000 | - |
| Other | ||||
| Issuance Of Debt | $99,965,000 | $0 | - | - |
| Interest Paid Supplemental Data | $8,900,000 | $11,506,000 | $26,717,000 | - |
| Income Tax Paid Supplemental Data | $2,000 | $2,000 | $3,000 | $4,000 |
| End Cash Position | $124,220,000 | $152,596,000 | $277,924,000 | $0 |
| Beginning Cash Position | $152,596,000 | $277,924,000 | $273,865,000 | $0 |
| Changes In Cash | $-28,376,000 | $-125,328,000 | $4,059,000 | - |
| Proceeds From Stock Option Exercised | $1,606,000 | $71,678,000 | $2,316,000 | - |
| Net Issuance Payments Of Debt | $99,965,000 | $0 | - | - |
| Net Long Term Debt Issuance | $99,965,000 | $0 | - | - |
| Long Term Debt Issuance | $99,965,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-28,000 | $-2,597,000 | $-4,593,000 | $-686,000 |
| Sale Of PPE | $3,000 | $0 | - | - |
| Purchase Of PPE | $-31,000 | $-2,597,000 | $-4,593,000 | $-686,000 |
| Change In Working Capital | $-7,614,000 | $52,051,000 | $15,348,000 | $3,858,000 |
| Change In Other Current Liabilities | $-1,595,000 | $-1,408,000 | $-1,860,000 | $-1,674,000 |
| Change In Other Current Assets | $0 | $-3,667,000 | $0 | $-1,317,000 |
| Change In Payables And Accrued Expense | $-7,662,000 | $53,786,000 | $28,180,000 | $6,923,000 |
| Change In Accrued Expense | $-4,361,000 | $35,883,000 | $26,071,000 | $7,301,000 |
| Change In Payable | $-3,301,000 | $17,903,000 | $2,109,000 | $-378,000 |
| Change In Account Payable | $-3,301,000 | $17,903,000 | $2,109,000 | $-378,000 |
| Change In Prepaid Assets | $1,400,000 | $2,982,000 | $-10,285,000 | $407,000 |
| Change In Receivables | $243,000 | $358,000 | $-521,000 | $621,000 |
| Changes In Account Receivables | $200,000 | $-185,000 | $-535,000 | $130,000 |
| Other Non Cash Items | $4,242,000 | $3,962,000 | $5,030,000 | $1,621,000 |
| Stock Based Compensation | $11,138,000 | $58,518,000 | $24,846,000 | $17,791,000 |
| Depreciation Amortization Depletion | $2,483,000 | $2,285,000 | $1,191,000 | $1,225,000 |
| Depreciation And Amortization | $2,483,000 | $2,285,000 | $1,191,000 | $1,225,000 |
| Gain Loss On Sale Of PPE | $12,000 | $12,000 | $3,000 | $19,000 |
| Gain Loss On Sale Of Business | $0 | $-1,998,809,000 | $0 | - |
| Net Income From Continuing Operations | $-140,055,000 | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Earnings Losses From Equity Investments | - | $0 | $1,634,000 | $0 |
| Change In Other Working Capital | - | - | $-166,000 | $-1,102,000 |
Fetched: 2026-06-25